Jobs

The pharma industry found it easier to fill AI vacancies in Q3 2022

The proportion of pharmaceutical companies hiring for cloud related positions rose to a year-high in August 2021, with 42.7% of the companies included in our analysis recruiting for at least one such position.

On a regional level, AI-related jobs were hardest to fill in Europe, where these roles were taken offline having been online for an average of 42.8 days.

Powered by 

Artificial intelligence related jobs that were closed during Q3 2022 had been online for an average of 36.5 days when they were taken offline. 

This was a decrease compared to the equivalent figure a year earlier, indicating that the required skillset for these roles has become easier to find in the past year. 

Artificial intelligence is one of the topics that GlobalData, our parent company and from whom the data for this article is taken, have identified as being a key disruptive technology force facing companies in the coming years. Companies that excel and invest in these areas now are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

On a regional level, these roles were hardest to fill in Europe, with related jobs that were taken offline in Q3 2022 having been online for an average of 42.8 days. 

The next most difficult place to fill these roles was found to be North America, while the Middle East and Africa was in third place. 

At the opposite end of the scale, jobs were filled fastest in South & Central America, with adverts taken offline after 20 days on average.

While the pharmaceutical industry found it easier to fill these roles in the latest quarter, these companies also found it easier to recruit artificial intelligence jobs than the wider market, with ads online for 13.1% less time on average compared to similar jobs across the entire jobs market. 

GlobalData's job analytics database tracks the daily hiring patterns of thousands of companies across the world, drawing in jobs as they're posted and tagging them with additional layers of data on everything from the seniority of each position to whether a job is linked to wider industry trends.

Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue